Velma Hughes
Psychiatric/Mental Health · Harlingen, TXNPI 1144717547
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Neurocrine Biosciences, Inc. accounts for 85.0% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $16,532 and has fallen 98.6% since, to $238 in 2025. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $114.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$25K
- Teva Pharmaceuticals USA, Inc.$2K
- AbbVie$593
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$433
- Takeda Pharmaceuticals U.S.A., Inc.$202
- Idorsia Pharmaceuticals US Inc$195
- plus $675 from 7 others
What the payments were for
- Consulting fees$10,12535%
- Speaking & faculty fees$13,21346%
- Travel & lodging$1,2564%
- Food & beverage$4,43115%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 103 | $24,662 |
| Teva Pharmaceuticals USA, Inc. | 25 | $2,265 |
| AbbVie | 43 | $593 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $433 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $202 |
| Idorsia Pharmaceuticals US Inc | 18 | $195 |
| Axsome Therapeutics, Inc. | 8 | $192 |
| Alkermes, Inc. | 9 | $175 |
| Lundbeck LLC | 10 | $152 |
| Corium, LLC | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Johnson & Johnson | 2 | $37 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,025 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 40 | $327,619 |
| AustedoDeutetrabenazine | 19 | $142,539 |
| CaplytaLumateperone Tosylate | 27 | $54,998 |
| TrintellixVortioxetine Hydrobromide | 50 | $31,371 |
| RexultiBrexpiprazole | 13 | $20,972 |
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $15,814 |
| Aripiprazole | 41 | $2,338 |
| Duloxetine Hcl | 26 | $1,402 |
| Paliperidone ErPaliperidone | 12 | $1,014 |
| Trazodone Hcl | 74 | $841 |
| Lorazepam | 90 | $742 |
| Bupropion XlBupropion Hcl | 26 | $684 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 21 | $495 |
| Quetiapine Fumarate | 35 | $493 |
| Hydroxyzine Pamoate | 38 | $481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $24,662 | $327,61940 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $2,265 | $142,53919 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $433 | $54,99827 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $202 | $31,37150 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $37 | $20,97213 claims |
| Axsome Therapeutics, Inc.Auvelity | $192 | $15,81414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Harlingen
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
- Jaime Nelson DensonAustin$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.